Compare Crispr Therapeutics AG (CRSP) vs HSBC Holdings plc (HSBC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs HSBC Holdings plc — how do they compare? Crispr Therapeutics AG trades at $53.39 (market cap $4.88B), while HSBC Holdings plc trades at $92.98 (market cap $311.92B). The key difference: HSBC Holdings plc is far larger — about 63.9× Crispr Therapeutics AG's market cap, and HSBC Holdings plc pays a 4.05% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals — on Pluang, investors hold Crispr Therapeutics AG for 77 Days and HSBC Holdings plc for 36 Days on average.
| CRSP | HSBC | |
|---|---|---|
Market Cap | $4.88B | $311.92B |
Volume | 2,861,747 | 3,546,658 |
Sector | Health | Financials |
52-Week High | $73.97 | $107.86 |
52-Week Low | $44.34 | $65.67 |
Typical Hold Time | 77 Days | 36 Days |
Enterprise Value | $3.30B | $222.19B |
Dividend Yield | — | 4.05% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRISPR Therapeutics (CRSP) trades at $50.44, down 3.65% amid bearish technical signals. The company shows negative profitability with -$581.60M net income and -4,101.26% net margin for 2025, though Q2 2026 EPS beat expectations. Positive analyst sentiment persists with 57.9% buy ratings and $67.83 consensus target. Recent clinical data presentations and CASGEVY commercial progress provide catalysts.
The stock faces fundamental challenges with persistent losses and negative cash flow from operations, but maintains Wall Street support for its gene-editing pipeline. Key risks include clinical trial outcomes and cash burn, while potential upside hinges on successful drug commercialization and upcoming data readouts through 2026.
HSBC trades at $92.61, down 1.17% over the past 24 hours, with technical indicators signaling a bearish trend. The company reported strong profitability with a net income margin of 34.54% and a P/E ratio of 13.23, reflecting reasonable valuation. Recent developments include expansion in technology banking and wealth management services, alongside strategic exits from non-core markets like Germany.
The outlook for HSBC is mixed; growth in wealth management and Asia presents opportunities, but bearish technicals and CFO transition in 2027 pose risks. Analyst sentiment is cautious with a majority hold rating, emphasizing the need for execution on strategic priorities to drive shareholder value amid global economic uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About HSBC Holdings plc
HSBC is one of the world's largest banking and financial services organizations. It serves customers worldwide through four global businesses: Retail, Commercial, Global Banking, and Private Banking.
Read more on HSBC →
